TCBP Current Deferred Revenue from 2010 to 2024
| TCBP Stock | USD 0.64 0.02 3.03% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter -274.8 K | Current Value -261.1 K | Quarterly Volatility 953.5 K |
Check TC BioPharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TC BioPharm's main balance sheet or income statement drivers, such as Interest Income of 1.9 K, Depreciation And Amortization of 638 K or Interest Expense of 78.9 K, as well as many indicators such as Price To Sales Ratio of 0.62, Dividend Yield of 0.0 or PTB Ratio of 0.3. TCBP financial statements analysis is a perfect complement when working with TC BioPharm Valuation or Volatility modules.
TCBP | Current Deferred Revenue |
Latest TC BioPharm's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of TC BioPharm Holdings over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. TC BioPharm's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TC BioPharm's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
TCBP Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 1,561,574 | |
| Coefficient Of Variation | 61.06 | |
| Mean Deviation | 736,786 | |
| Median | 2,030,746 | |
| Standard Deviation | 953,515 | |
| Sample Variance | 909.2B | |
| Range | 2.3M | |
| R-Value | (0.70) | |
| Mean Square Error | 496.3B | |
| R-Squared | 0.49 | |
| Significance | 0 | |
| Slope | (149,717) | |
| Total Sum of Squares | 12.7T |
TCBP Current Deferred Revenue History
About TC BioPharm Financial Statements
TC BioPharm shareholders use historical fundamental indicators, such as Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although TC BioPharm investors may analyze each financial statement separately, they are all interrelated. The changes in TC BioPharm's assets and liabilities, for example, are also reflected in the revenues and expenses on on TC BioPharm's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -274.8 K | -261.1 K |
Pair Trading with TC BioPharm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if TC BioPharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in TC BioPharm will appreciate offsetting losses from the drop in the long position's value.Moving together with TCBP Stock
| 0.67 | A | Agilent Technologies Sell-off Trend | PairCorr |
| 0.85 | ME | 23Andme Holding | PairCorr |
| 0.76 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against TCBP Stock
| 0.67 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.46 | KZR | Kezar Life Sciences | PairCorr |
| 0.41 | MLYS | Mineralys Therapeutics, | PairCorr |
| 0.37 | KEP | Korea Electric Power | PairCorr |
The ability to find closely correlated positions to TC BioPharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace TC BioPharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back TC BioPharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling TC BioPharm Holdings to buy it.
The correlation of TC BioPharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as TC BioPharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if TC BioPharm Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for TC BioPharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for TCBP Stock Analysis
When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.